US · AGPU
Axe Compute Inc.
- Sector
- Technology · Software - Infrastructure
- Headquarters
- Pittsburgh, PA 15201
- Website
- axecompute.com
Price · as of 2024-12-31
$5.52
Market cap 6.38M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $32.10 | +481.52% |
| Intrinsic Value(DCF) | $6.84 | +23.91% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | $450,000.00 | $392,559.86 | $0.00 | $0.00 | $52,280.38 |
| 2011 | $483,750.00 | $2,355,254.70 | $2,925,635.62 | $0.00 | $0.00 |
| 2012 | $421,875.00 | $282,842.93 | $236,166,795.03 | $0.00 | $0.00 |
| 2013 | $1,237,500.00 | $504,958.58 | $20,980,633,955.18 | $0.00 | $0.00 |
| 2014 | $295,050.00 | $133,282.07 | $5,006,607,494.93 | $0.00 | $0.00 |
| 2015 | $13,500.00 | $8,844.15 | $1,037,462.51 | $0.00 | $6,661.35 |
| 2016 | $6,330.00 | $40,197.08 | $63,941.52 | $0.00 | $9,596.69 |
| 2017 | $4,044.00 | $1,617.60 | $36,083.67 | $0.00 | $0.00 |
| 2018 | $2,400.00 | $1,233.61 | $504,507.98 | $0.00 | $0.00 |
| 2019 | $747.00 | $730.15 | $1.67 | $0.00 | $0.00 |
| 2020 | $501.00 | $238.46 | $0.00 | $0.00 | $114.28 |
| 2021 | $279.00 | $126.70 | $25.50 | $0.00 | $0.00 |
| 2022 | $93.00 | $46.82 | $0.39 | $0.00 | $0.00 |
| 2023 | $43.65 | $38.10 | $0.85 | $0.00 | $0.00 |
| 2024 | $17.10 | $32.10 | $0.00 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Axe Compute Inc.'s (AGPU) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $32.10
- Current price
- $5.52
- AI upside
- +481.52%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$6.84
+23.91% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| AGPU | Axe Compute Inc. | $5.52 | 6.38M | +482% | +24% | — | — | -8.59 | -460.28 | 57.43 | -9.24 | — | -225.96 | 49.12% | -673.69% | -751.39% | -269.18% | -631.77% | -112.02% | -10.52 | — | 0.62 | 0.41 | -0.14 | -3563.00% | -24.00% | -943.00% | -12.83% | -3.33 | -691.01% | 0.00% | 0.00% | 0.00% | -8.65 | -7.91 | 58.29 | -47.25 |
| AMIX | Autonomix Medical, Inc. C… | $0.44 | 2.26M | — | — | — | — | -0.23 | 0.32 | — | 0.59 | — | 0.32 | 0.00% | — | — | -145.10% | 2283.35% | -118.77% | 0.00 | -65.84 | 5.63 | 5.35 | 0.83 | -6937.00% | — | 2407.00% | -316.49% | -4.84 | 1629.95% | 0.00% | 0.00% | 58.54% | 0.56 | 0.79 | — | -9.21 |
| BNGO | Bionano Genomics, Inc. | $1.15 | 3.78M | +6,408% | +42% | — | +30,750% | -0.07 | 0.22 | 0.25 | -0.26 | — | 0.30 | 1.23% | -337.87% | -363.98% | -170.33% | -128.38% | -76.97% | 0.77 | -359.80 | 1.06 | 0.38 | -0.19 | -9964.00% | -1479.00% | -4559.00% | -889.15% | -1.85 | -85.22% | 0.00% | 0.00% | 558.30% | -0.25 | -0.37 | 0.83 | -16.59 |
| CYCN | Cyclerion Therapeutics, I… | $1.35 | 5.14M | — | +2,196,706% | — | — | -2.31 | 0.80 | 3.53 | -1.05 | — | 0.80 | 100.00% | -181.40% | -152.85% | -30.36% | -77.73% | -26.64% | 0.00 | — | 5.83 | 5.22 | 0.89 | -8654.00% | — | -7960.00% | -61.46% | -5.98 | -92.83% | 0.00% | 0.00% | 0.00% | -1.05 | -0.88 | 1.91 | -33.88 |
| HSCS | HeartSciences Inc. | $2.79 | 6.25M | +699% | -40% | — | +21,742% | -0.45 | 19.02 | 897.28 | -0.71 | — | -2.77 | -2884.71% | -192013.13% | -201499.52% | -233.04% | -360.16% | -127.72% | 14.55 | -16.69 | 0.59 | 0.30 | -0.23 | -5016.00% | -7661.00% | 2014.00% | -190.70% | -2.00 | -320.95% | 0.00% | 0.00% | 0.00% | -0.69 | -0.78 | 1331.10 | -31.62 |
| KTTA | Pasithea Therapeutics Cor… | $0.88 | 6.56M | — | — | — | — | -0.09 | 0.09 | — | 0.41 | — | 0.21 | 0.00% | — | — | -72.83% | -189.89% | -65.93% | 0.00 | — | 6.58 | 6.18 | 0.51 | -246.00% | — | 345.00% | -1067.47% | -12.43 | -185.53% | 0.00% | 0.00% | 0.00% | 0.39 | 0.40 | — | -6.17 |
| MYNZ | Mainz Biomed B.V. | $0.76 | 3.11M | +29,917% | +195% | — | — | -0.25 | 0.90 | 6.08 | -0.13 | -0.02 | 1.79 | 64.31% | -2091.23% | -2421.80% | -465.82% | -559.63% | -151.15% | 0.54 | -17.39 | 1.32 | 1.08 | 0.15 | 128025.00% | -17.00% | -2724.00% | -319.32% | -2.87 | -519.21% | 0.00% | 0.00% | 61.01% | -0.13 | -0.14 | 2.76 | -13.59 |
| TCRT | Alaunos Therapeutics, Inc… | $3.19 | 7.12M | +18,244% | -80% | — | — | -0.55 | 1.26 | 259.40 | -0.32 | — | 1.26 | 100.00% | -48120.00% | -46790.00% | -111.80% | -790.80% | -84.93% | 0.00 | — | 3.98 | 1.58 | 0.23 | -8671.00% | 10000.00% | -8362.00% | -191.63% | -7.18 | -816.93% | 0.00% | 0.00% | 0.00% | -0.31 | -0.30 | 150.30 | -470.35 |
| VYNE | VYNE Therapeutics Inc. | $0.60 | 10.01M | +3,912% | -43% | — | — | -0.98 | 0.93 | 45.39 | 0.12 | — | 0.93 | 0.00% | -4690.53% | -4646.14% | -66.33% | 505.69% | -54.57% | 0.00 | — | 12.53 | 12.11 | 0.90 | -3404.00% | 1377.00% | -283.00% | -128.02% | -13.83 | 626.52% | 0.00% | 0.00% | 16.23% | 0.12 | 0.09 | -5.50 | -30.50 |
About Axe Compute Inc.
Axe Compute Inc., a knowledge and science-driven company, applies artificial intelligence (AI) to support the discovery and development of cancer therapies. It operates through two segments, Pittsburgh and Eagan. The Pittsburgh segment provides services that include the application of AI using its proprietary biobank of 150,000+ tumor samples. This segment also creates proprietary 3D culture models used in drug development. Its Eagan segment produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. Predictive Oncology Inc. has a strategic collaboration with Every Cure to identify and prioritize drugs for repurposing. The company was formerly known as Predictive Oncology Inc. and changed its name to Axe Compute Inc. in December 2025. Axe Compute Inc. was incorporated in 2002 and is headquartered in Pittsburgh, Pennsylvania.
- CEO
- Christopher Miglino
- Employees
- 23
- Beta
- 1.35
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($6.84 ÷ $5.52) − 1 = +23.91% (DCF, example).